$PTCT News

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

PTC Therapeutics To Acquire BLA-Stage ST-920 Fabry Disease Program; Terms Include $111M Upfront And Up To $100M In Contingent Milestone Payments Based On Certain Regulatory Approvals

PTC Therapeutics (PTCT) Stock Fair Value Edges Higher After Analyst Target Increases

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics Q2 Earnings Call Highlights

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106

PTC Therapeutics Inc (PTCT) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

PTC Therapeutics (NASDAQ:PTCT) Soars on Q2 Earnings Beat and Raised Guidance

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTC Therapeutics Raises FY2026 Sales Guidance from $1.080B-$1.180B to $1.180B-$1.280B vs $1.196B Est

Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $93

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $130